Zai Lab's ZL-1503 heads to H2 2026 safety readout in atopic dermatitis
The Phase 1/1b trial will report first-in-human safety and tolerability data that Zai Lab says will set up Phase 2 testing in atopic dermatitis patients.
Executive Summary
- Zai Lab is running a first-in-human trial of ZL-1503, a bispecific antibody, in healthy volunteers and atopic dermatitis patients, with the initial safety data expected within the current half-year window.
- The registered primary endpoints are safety measures including adverse events, lab abnormalities, and vital-sign changes, not a measure of skin-clearance efficacy, so the readout is a tolerability gate rather than a proof-of-concept signal.
- No competing program in atopic dermatitis or in the broader inflammatory-skin-disease family shares both the IL-13 and IL-31R targets, leaving ZL-1503 without a direct precedent to benchmark against in this specific combination.
- The trial has moved cleanly from Not yet recruiting to Recruiting, holds its enrollment target unchanged, and the sponsor has repeated the same guidance window across three disclosures, all consistent with a program executing on plan rather than one showing distress.
The catalyst
Zai Lab Limited said it expects to report first-in-human data for ZL-1503 in healthy volunteers in the second half of 2026, according to a presentation at the J.P. Morgan Healthcare Conference on January 13, 2026. The trial, registered as NCT07235384, is a Phase 1/1b study evaluating safety, tolerability, and pharmacokinetics of ZL-1503 in healthy volunteers and in participants with moderate to severe atopic dermatitis. The company has repeated the same H2-2026 guidance window in disclosures dated January, February, and May 2026. Zai+1Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare ConferenceJan 13, 2026A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic DermatitisNCT07235384
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the readout will test
The trial's registered primary endpoints are the number of participants with adverse events, clinical laboratory abnormalities, ECG abnormalities, serious adverse events, and vital-sign abnormalities. That endpoint set makes this a safety and tolerability readout, not an efficacy signal: the design carries no primary measure of disease severity such as EASI or vIGA-AD score, though the eligibility criteria require enrolled atopic dermatitis patients to have an EASI score of 16 or higher and a vIGA-AD score of 3 or higher at baseline. Zai Lab has said the data will pave the way for Phase 2 development in atopic dermatitis patients, though it has disclosed no explicit regulatory filing plans tied to this readout. NCT07235384+1A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic DermatitisNCT07235384Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare ConferenceJan 13, 2026
Trial status and enrollment
The trial moved from Not yet recruiting to Recruiting on December 19, 2025, and enrolled its first participant on December 8, 2025. Enrollment is targeted at 84 participants, unchanged since the trial's registration, and the trial's primary completion date is listed as December 28, 2027, well beyond the guided data-readout window. The trial spans two protocol amendments on record, both administrative in nature, and carries no history of endpoint changes or completion-date revisions. NCT07235384A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic DermatitisNCT07235384
Competitive position
No trial in the atopic dermatitis competitive field shares ZL-1503's combination of IL-13 and IL-31R targeting; the closest named comparators, including dupilumab (targeting IL-4Rα) and nemolizumab (targeting IL-31RA alone), work through different or partial mechanisms. The atopic dermatitis field itself is active, with 146 trials tracked across the indication and IL-13, JAK1, and IL-4Rα as the most frequently targeted mechanisms. ZL-1503's dual-target approach sits without a direct precedent in this specific combination, placing this readout in mechanistically uncharted territory for the target pairing rather than in a crowded field of like mechanisms.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.